All News

Lung carcinoid tumors are rare and often slow growing. Treatment depends on stage and tumor type, with surgery common early and systemic options for advanced disease.

Dr. Suneel Kamath highlighted advances in biomarker-driven therapies and emerging frontline regimens following the 2026 ASCO GI Cancers Symposium.

Adding Ibrance to maintenance therapy extends the time some patients with metastatic breast cancer live without their disease progressing.

Risk assessment helps patients understand why cancer occurred, the role of genetics, treatment options and prevention strategies for themselves and family.

I’m preparing for something I once only dreamed about, my final visit to the cancer treatment center.

Dr. Brittany Dulmage explains how biotin can interfere with lab testing and discusses safer, evidence-based options for managing cancer-related hair loss.

The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after prior targeted treatment.

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Dr. Suneel Kamath discusses the importance of biomarker-driven approaches in cancer care following the 2026 ASCO GI Symposium.

Dr. Tracy Proverbs-Singh explains that caregivers may neglect screenings, medications, rest, and hydration, risking their own health.

A breast cancer survivor detects her first pre-cancerous skin lesion, highlighting the importance of self-checks and regular dermatology visits.

The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma.

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric patients with T-ALL and T-LBL.

Dr. Ariel Ostad explains how addressing uncertainty and scananxiety through communication and support can improve the cancer care experience for patients.

Dr. Tracy Proverbs-Singh explains how a multidisciplinary team helps patients with GI cancers manage digestion, absorb nutrients and maintain energy during treatment.

Kim Johnson shares her experience losing her sister to cancer, offering guidance for those grieving and for the people supporting them.

A phase 2 trial showed onvansertib plus FOLFIRI and Avastin improved response and disease control in first-line RAS-mutated metastatic colorectal cancer.

The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

The NCCN Clinical Practice Guidelines in Oncology now include Besremi as a Category 1 preferred treatment option for some with high-risk essential thrombocythemia.

Dr. Anne Peled, a two-time breast cancer survivor, underwent a sensation-preserving mastectomy, a procedure she co-developed.

The FDA granted breakthrough therapy designation to bezuclastinib plus Sutent for patients with gastrointestinal stromal tumors following progression.

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.

Dr. Anne Peled shares advice for patients and dispelled myths related to cancer survivorship.

If you’re struggling out there, feeling a little broken inside, I see you. And if you’re not, man, I wish I were you.

As patients with advanced cancer near the end of life, reducing unnecessary medications may help prioritize comfort, quality of life and symptom relief.

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

This weekend, January 30 - February 1, join thousands of runners, walkers, survivors and spectators for the 19th Annual DONNA Marathon Weekend.

Among patients with advanced breast cancer, levels of circulating tumor DNA before treatment may predict their response to targeted therapy.